Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Cannibidiol is All the Rage – Is Pharma Getting in on the CBD Craze?

Posted on August 14th, 2019 by

Pharma R&D

Few substances on earth have been surrounded by more confusion than marijuana. Harmless plant or illicit drug? Medicinal or recreational? Legal or illegal (or partially legal)? And what should we make of all these things associated with marijuana, like hemp and CBD oil?

(more…)

The Beneficial Impacts of Real-World Evidence in Drug Development

Posted on August 1st, 2019 by

Pharma R&D

Advances in technology, increased investment in digital solutions and the creation of more powerful analytics are all contributing to a growing interest in utilizing real-world evidence (RWE) in drug discovery & development. Following up on my previous post that goes into detail on what RWE is and why the industry is increasingly drawn to it, I now want to discuss its role and impact in the drug development life cycle.

(more…)

Why is the Pharma Industry Buzzing About Real-World Evidence?

Posted on July 30th, 2019 by

Pharma R&D

You have almost certainly heard the terms Real-World Data (RWD) and Real-World Evidence (RWE) – but are you still unsure about exactly what these things are and why they’re important? Let’s break it down.

(more…)

Global Dominance in AI? China’s Got a Plan For That

Posted on July 9th, 2019 by

Pharma R&D

Artificial intelligence is more than just a ‘hot topic’ in the pharmaceutical industry—it is actually influencing the way that major industry players and even entire nations are thinking about the future. As more AI-focused companies are launching, and as investment in AI technology is increasing in the US and EU, China is speeding up its efforts to ensure that it can be competitive in this burgeoning area.

(more…)

Is Bacteria in the Gut Compromising the Efficacy and Safety of the Drugs We Take?

Posted on July 2nd, 2019 by

Pharma R&D

Even the most reliable drugs don’t work exactly the same for everyone who takes them. The reason for this is an ongoing mystery, but a new study just published in Nature suggests that it may have a lot to do with the microbiome.

(more…)

How Can the Life Sciences Benefit from Using Simulated Data?

Posted on June 28th, 2019 by

Pharma R&D

The life sciences, like many sectors, are putting a higher and higher premium on good data. In our digital world, access to reliable data is a necessity, whether it’s healthcare providers counting on data analytics to inform patient care or drug developers requiring insightful data to create effective new therapies.

(more…)

  1. 1
  2. 2
  3. 3
  4. 66


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.